Skip to agency navigation
Skip to main content

Official Website

of the Commonwealth of Pennsylvania

    The .gov means its official.

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

    Local, state, and federal government websites often end in .gov. Commonwealth of Pennsylvania government websites and email systems use "pennsylvania.gov" or "pa.gov" at the end of the address. Before sharing sensitive or personal information, make sure you're on an official state website. 

     
    Councils & Committees

    ​Pharmacy and Therapeutics (P&T) Committee

    P&T Committee Meeting Information

    Upcoming Meetings

    Dates

    • Tuesday, September 10, 2024; 12 p.m.-4 p.m.
    • Wednesday, September 11, 2024; 9 a.m.-4 p.m. 

    Location

    The September P&T Committee meetings will be held virtually

    Register for the Webinars

    Public Testimony

    All members of the public may register to provide verbal or written testimony related to a drug or class of drugs included on the Statewide PDL at the P&T Committee meetings. Registration to present testimony during the meetings must be received by Tuesday, August 27, 2024. To register, please go to www.papdl.com and select "Public Testimony Registration." Written testimony will be accepted and must be submitted by Tuesday, August 27, 2024. Written testimony submissions will be distributed to all P&T Committee members prior to the meetings. All written testimony should be emailed to ra-pharmforms@pa.gov.

    Drug Classes

    Acne Agents, Oral

    Colony Stimulating Factors

    Migraine Acute Treatment Agents

    Acne Agents, Topical

    Continuous Glucose Monitors Products

    Migraine Prevention Agents

    Alcohol Use Disorder Agents

    Contraceptives, Oral

    Monoclonal Antibodies (MABs) – Anti-IL, Anti-IgE, Anti-TSLP

    Alzheimer’s Agents

    Contraceptives, Other

    Multiple Sclerosis Agents

    Analgesics, Non-Opioid Barbiturate Combinations

    COPD Agents

    Neuropathic Path Agents

    Analgesics, Opioid Long-Acting

    Cytokine and CAM Antagonists

    NSAIDs

    Analgesics, Opioid Short-Acting

    Dry Eye Treatments

    Obesity Treatment Agents

    Androgenic Agents

    Enzyme Replacement, Gaucher Disease

    Oncology Agents, Breast Cancer

    Angiotensin Modulator Combinations

    Epinephrine, Self-Injected

    Oncology Agents, Oral

    Angiotensin Modulators

    Erythropoiesis Stimulating Agents

    Ophthalmics, Allergic Conjunctivitis

    Antianginal Agents

    Estrogens

    Ophthalmics, Antibiotics

    Antibiotics, GI and Related Agents

    Fluoroquinolones, Oral

    Ophthalmics, Antibiotic-Steroid Combinations

    Antibiotics, Inhaled

    GI Motility, Chronic Agents

    Ophthalmics, Anti-Inflammatories

    Antibiotics, Topical

    Glucocorticoids, Inhaled

    Ophthalmics, Glaucoma

    Anticoagulants

    Glucocorticoids, Oral

    Opioid Overdose Agents

    Anticonvulsants

    Growth Hormones

    Opioid Use Disorder Treatments

    Antidepressants, Other

    H. Pylori Treatments

    Otic Antibiotic Preparations

    Antidepressants, SSRIs

    Hematopoietic Mixtures

    Pancreatic Enzymes

    Antiemetics/Antivertigo Agents

    Hepatitis B Agents

    Penicillins

    Antifibrotic Respiratory Agents

    Hepatitis C Agents

    Phosphate Lowering Agents

    Antifungals, Oral

    Hereditary Angioedema (HAE) Agents

    Pituitary Suppressive Agents, LHRH

    Antifungals, Topical

    Histamine 2 Receptor Blockers

    Platelet Aggregation Inhibitors

    Antihemophilia Agents

    HIV/AIDS Antiretrovirals

    Potassium Removing Agents

    Antihistamines, Minimally Sedating

    Hypoglycemia Treatments

    Prenatal Vitamins

    Antihypertensives, Sympatholytic

    Hypoglycemics, Alpha-Glucosidase Inhibitors

    Progestational Agents

    Antihyperuricemics

    Hypoglycemics, Incretin Mimetics/Enhancers

    Proton Pump Inhibitors (PPIs)

    Antimalarials

    Hypoglycemics, Insulin and Related Agents

    Pulmonary Hypertension Agents, Oral and Inhaled

    Antiparasitics, Topical

    Hypoglycemics, Meglitinides

    Sedative Hypnotics

    Antiparkinson’s Agents

    Hypoglycemics, Metformins

    Sickle Cell Anemia Agents

    Antipsoriatics, Oral

    Hypoglycemics, SGLT2 Inhibitors

    Skeletal Muscle Relaxants

    Antipsoriatics, Topical

    Hypoglycemics, Sulfonylureas

    Smoking Cessation Products

    Antipsychotics

    Hypoglycemics, TZDs

    Steroids, Topical

    Antivirals, CMV

    Immunomodulators, Atopic Dermatitis

    Stimulants and Related Agents

    Antivirals, Herpes

    Immunomodulators, Topical

    Tetracyclines

    Antivirals, Influenza

    Immunosuppressives, Oral

    Thalidomide and Derivatives

    Anxiolytics

    Intra-Articular Hyaluronates

    Thrombopoietics

    Benign Prostatic Hyperplasia (BPH) Treatments

    Intranasal Rhinitis Agents

    Thyroid Hormones

    Beta Blockers

    Iron Chelating Agents

    Tubeless Insulin Delivery Devices

    Bile Salts

    Iron, Parenteral

    Ulcerative Colitis Agents

    Bladder Relaxant Preparations

    Leukotriene Modifiers

    Urea Cycle Disorder Agents

    Blood Glucose Meters and Test Strips

    Lipotropics, Other

    Urinary Anti-Infectives

    Bone Density Regulators

    Lipotropics, Statins

    Vaginal Anti-Infectives

    Botulinum Toxins

    Local Anesthetics, Topical

    Vitamin D Analogs

    Bronchodilators, Beta Agonists

    Macrolides

    VMAT2 Inhibitors

    Calcium Channel Blockers

    Macular Degeneration Agents

     

    Cephalosporins

    Methotrexate

     

    Related Links

    The Department of Human Services (Department) appointed the P&T Committee to act in an advisory capacity to the Department and the Office of Medical Assistance Programs (OMAP) and provide an unbiased clinical perspective on the Department's Statewide Preferred Drug List (PDL). Recommendations from the committee must be reviewed and approved by the Secretary of the Department of Human Services.

    Change Healthcare provides clinical and financial analysis support to the P&T Committee.

    Committee Information

    Composition and responsibilities of the committee:

    • Comprised of department medical directors, external physicians, pharmacists, consumer advocates, and specialists as needed for drug class reviews.
    • Recommend a clinically-based PDL with an emphasis on effectiveness, safety, and outcomes.
    • Recommend prior authorization guidelines for non-preferred drugs as well as certain preferred drugs using current community standards for prescribing.
    • Recommend Prospective and Retrospective Drug Utilization Review Program Review and Development.

     

    Name

    Specialty

    Independent*

    Department**

    MCO

    Ivonne Acrich, MD

    OMHSAS Child/Adolescent Psychiatrist

     

    X

     

    ​Dale Adair, MD, FAPA

    ​Office of Mental Health & Substance Abuse Services Medical Director

    ​

    ​X

    ​

    Christopher Antypas, PharmD

    Community Pharmacist

    X

     

     

    Lawrence Appel, MD, SFHM

    Medical Director, Office of Long Term Living

     

    X

     

    Meghan Brenkle, PharmD

    		PA Health & Wellness Pharmacist  X

    Terri Cathers, PharmD,
    Chair (tie-breaker vote only)

    OMAP Pharmacy Director

     

    X

     

    ​Michael Colvin, PharmD

    ​AmeriHealth Caritas & Keystone First HealthChoices & Community HealthChoices Pharmacist

    ​

    ​

    ​X

    Sharon Connor, PharmD

    Academic Pharmacist

    X

     

     

    ​Molly DiMatteo, DO

    ​Family Practitioner

    ​X

    ​

    ​

    ​Oluwatoyin Fadeyibi, PharmD, MPH

    ​Community Behavioral Health Pharmacist

    ​

    ​

    ​X

    Andrea Fox, MD

    Internist

    X

     

     

    Mark Fuller, MD

    		Carelon Health of PA Medical Director      X

    Donald Gerhart, RPh

    Community Pharmacist

    X

     

     

    James Hancovsky, RPh, MBA

    United Health Care Pharmacy Director

     

     

    X

    ​David Kelley, MD

    ​OMAP Chief Medical Officer, Office of Medical Assistance Programs

    ​

    ​X

    ​

    Chen Kenyon, MD, MSHPPediatricianX  

    Peter Kreckel, RPh

    Community Pharmacist

    X

     

     

    Renee Licwinko, RPh

    Gateway Health Plan Pharmacist

     

     

    X

    Michele Musheno, RPh, MS

    Academic/Hospital Pharmacist

    X

     

     

    ​Geoffrey Neimark, MD

    ​Community Care Behavioral Health Psychiatrist

    ​

    ​

    ​X

    Ian Paul, MD, Vice Chair

    Pediatrician

    X

     

     

    Adam Raphael Rom, MD

    Family Practitioner

    X

     

     

    Amy Saracino, DO

    OMHSAS Adult Psychiatrist

     

    X

     

    John Shand, MDPerformCare PA Medical Director  X

    ​Christopher Squillaro, DO

    ​Magellan Behavioral Health of PA Medical Director

    ​

    ​

    ​X

    Kevin Szczecina, RPh

    Geisinger Health Plan Pharmacist

     

     

    X

    ​Fallan Vaisberg, PharmD, RPh

    ​Health Partners Plans Formulary Pharmacist

    ​

    ​

    ​X

    Andreas Wali, MD

    ​Cardiologist

    ​X

    ​

    ​

    Verlyn Warrington, MD

    Bariatric Medicine Specialist/Family Medicine Doctor

    X

     

     

    Lloyd Wertz

    Consumer/Family Advocate

    X

     

     

    ​Lauren Zandier, PharmD

    ​UPMC For You Pharmacist

    ​

    ​

    ​X

    Vacant

    Consumer Representative

    X

     

     

    * - Independent Members are not employed by the Department
    ** - Department Members are employed by the Department on a full or part-time basis

    Effective August 23, 2024 / Last modified August 16, 2024